DM-919 is under clinical development by D2M Biotherapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how DM-919’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DM-919 overview
DM-919 is under development for the treatment of solid tumor. The therapeutic candidate is a monoclonal antibody which acts by targeting MHC class I polypeptide related sequence A and MHC class I polypeptide related sequence B (MICA/B).It is administrated by intravenous route.
D2M Biotherapeutics overview
D2M Biotherapeutics is a biotechnology company which focuses on immunology, human genetics, immunology-oncology, inflammatory disease, and antibody discovery. D2M Biotherapeutics is headquartered in Natick, Massachusetts, the US.
For a complete picture of DM-919’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
